share_log

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

艾伯維公司 | 8-K:艾伯維公司指導方針包括收購知識產權研發和裏程碑支出的影響
美股sec公告 ·  07/03 14:10
Moomoo AI 已提取核心訊息
AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
艾伯維公司已於2024年7月3日發佈了一份初步報告,詳細說明了2024年第二季度預期財務結果。報告包括預計會對GAAP和非GAAP稀釋每股收益造成52美分的收購知識產權研發和里程碑費用93700萬美元的稅前影響。截至2024年6月30日的季度結果尚未最終確定,並且正在進行財務報表結算程序。艾伯維公司已將其2024年全年調整後稀釋每股收益指導範圍更新爲10.61至10.81美元,包括第二季度收購的知識產權研發和里程碑費用的影響。第二季度調整後每股收益指導範圍設定在2.53至2.57美元之間。該公司此前已宣佈,其於2024年4月26日宣佈的2024年調整後稀釋每股收益指導不包括第一季度以外的任何收購知識產權研發和里程碑費用的影響。艾伯維公司的前瞻性陳述存在風險和不確定因素,可能導致實際結果與預期相差甚遠。
艾伯維公司已於2024年7月3日發佈了一份初步報告,詳細說明了2024年第二季度預期財務結果。報告包括預計會對GAAP和非GAAP稀釋每股收益造成52美分的收購知識產權研發和里程碑費用93700萬美元的稅前影響。截至2024年6月30日的季度結果尚未最終確定,並且正在進行財務報表結算程序。艾伯維公司已將其2024年全年調整後稀釋每股收益指導範圍更新爲10.61至10.81美元,包括第二季度收購的知識產權研發和里程碑費用的影響。第二季度調整後每股收益指導範圍設定在2.53至2.57美元之間。該公司此前已宣佈,其於2024年4月26日宣佈的2024年調整後稀釋每股收益指導不包括第一季度以外的任何收購知識產權研發和里程碑費用的影響。艾伯維公司的前瞻性陳述存在風險和不確定因素,可能導致實際結果與預期相差甚遠。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息